Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251 [PMID: 36387806 DOI: 10.12998/wjcc.v10.i31.11240]
Corresponding Author of This Article
Jin-Chun Liu, MD, Chief Doctor, Full Professor, Department of Gastroenterology, The First Hospital of Shanxi Medical University, No. 85 Jiefangnan Road, Taiyuan 030001, Shanxi Province, China. zxr610624@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2022; 10(31): 11240-11251 Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11240
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Jin-Chun Liu
Ji-Shuai Wang, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Jin-Chun Liu, Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Author contributions: Wang JS wrote original draft and data curation; Liu JC contributed the conceptualization.
Supported bythe Scientific and Technological Achievements Transformation Guidance Special of Shanxi Province in China, No. 201904D131030.
Conflict-of-interest statement: All authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Chun Liu, MD, Chief Doctor, Full Professor, Department of Gastroenterology, The First Hospital of Shanxi Medical University, No. 85 Jiefangnan Road, Taiyuan 030001, Shanxi Province, China. zxr610624@163.com
Received: July 30, 2022 Peer-review started: July 30, 2022 First decision: September 2, 2022 Revised: September 7, 2022 Accepted: September 27, 2022 Article in press: September 27, 2022 Published online: November 6, 2022 Processing time: 88 Days and 13.8 Hours
Abstract
Metabolically associated fatty liver disease (MAFLD) is a common cause of chronic liver disease, the hepatic manifestation of metabolic syndrome. Despite the increasing incidence of MAFLD, no effective treatment is available. Recent research indicates a link between the intestinal microbiota and liver diseases such as MAFLD. The composition and characteristics of the intestinal microbiota and therapeutic perspectives of MAFLD are reviewed in the current study. An imbalance in the intestinal microbiota increases intestinal permeability and exposure of the liver to adipokines. Furthermore, we focused on reviewing the latest "gut-liver axis" targeted therapy.
Core Tip: Recent animal studies and Clinical researches have placed the gut microbiota as a potentially important player in the pathogenesis of metabolically associated fatty liver disease (MAFLD). It is logical to target the gut microbiota to develop new strategies for MAFLD therapy. In addition, we assessed the therapeutic potential of intestinal microbiota manipulation for treating MAFLD and discussed the specific doses and duration of use can provide more help for clinicians in choosing treatment options.
